FDA-Cleared Blood Tests Accelerate Alzheimer’s Detection and Trial Recruitment

C2N’s PrecivityAD2 detects amyloid in symptomatic adults as young as 40, while Roche and Eli Lilly’s Elecsys pTau217 received FDA clearance on August 24, 2026, for symptomatic adults aged 55 and older. Current commentary reinforces that blood tests belong after objective impairment and clinical workup, not in asymptomatic population screening; Medicare-coverage advocacy remains a proposal, not law.